Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1990-04-18
1992-02-04
Rollins, John W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514934, A61K 3170
Patent
active
050860445
ABSTRACT:
Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof. Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose. Additionally, there is disclosed the treatment of Kaposi's sarcoma with 3'-azido-3'-deoxythymidine (AZT) and the synergistic activity in the treatment of humans infected with HTLV-III of AZT and interferon as well as AZT and acyclovir.
REFERENCES:
patent: 4724232 (1988-02-01), Rideout et al.
Hartshorn et al., Antimicrobial Agents of Chemotherapy, vol. 31, No. 2, Feb., 1987, Synergistic Inhibition of Human Immunodeficiency Virus In Vitro by Azidothymidine and Recombinant Alpha A Interferon, pp. 168-172.
Lane et al., The Lancet, Nov. 26, 1988, Anti-Retroviral Effects of Interferon-.alpha.In Aids-Associated Kaposi's Sarcoma, pp. 1218-1222.
DeWit et al., The Lancet, Nov. 26, 1988, Clinical and Virological Effects of High-Dose Recombinant Interferon-.alpha.In Disseminated Aids-Related Kaposi's Sarcoma, pp. 1214-1217.
Paper--J. Interferon Res. 7(6):774, 1987.
J. M. Yeo, Journal of Infec., 1989, 18, Supplement 1, pp. 93-96, Current and future trials with zidovudine.
Ho et al., The Lancet, Mar. 16, 1985, Recombinant Human Interferon Alfa-A Suppresses HTLV-III Replication in Vitro, pp. 602-604.
Zidovudine/Interferon Combination Therapy, Apr. 17, 1988, 17 pages.
Orholm et al., Current Science Ltd., vol. 3, No. 2, Suppression of p. 24 Antigen in Sera from HIV-Infected individuals with low-dose.alpha.-interferon and zidovudine: a pilot study, pp. 97-100.
Paper--The Lancet, Jan. 21, 1989, Interferon-Alpha Plus Zidovudine in HIV Infection, page 156.
Paper--Carron et al., No. 3633, Anti-HIV Activity of Beta-Interferon in Combination with Zidovudine.
Paper--vol. 260, No. 23, Dec. 16, 1988, From the National Institutes of Health, Progress in Aids Research, p. 3406.
Dozier et al., Drug. Intell. Clin. Pharm., 17(11), pp. 798-807, Nov., 1983, Acquired Immune Deficiency Syndrome and the Management of Associated Opportunistic Infections.
Paper--The Lancet, Jan. 30, 1988, Combination Therapy After Retroviral Inoculation, pp. 239-240.
Daul et al., Annals of Allergy, vol. 51, Sep. 1983, Acquired Immune Deficiency Syndrome: An Update and Interpretation, pp. 351-361.
Paper--C-21, Aids, Proceedings of Asco, vol. 4, Mar. 1985.
Barry David W.
Furman Phillip A.
Lehrman Sandra N.
Rideout Janet L.
St. Clair Martha H.
Brown Donald
Burroughs Wellcome Co.
Nielsen Lawrence A.
Rollins John W.
LandOfFree
Treatment of human viral infections does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of human viral infections, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of human viral infections will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-348042